#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Transfusion and Haematology Today / 2024 - Ahead of Print

Measuring factor VIII activity in patients with severe haemophilia A treated with extended half-life concen-trates – comparison of selected assay results

Czech version

Authors: M.. Prudková 1-3;  P. Smejkal 1,3;  D. Chytrá 1,3;  J. Zavřelová 1,3;  G. Romanová 1-3;  M. Penka 1,2;  A. Buliková 1,2
Authors‘ workplace: Oddělení klinické hematologie, FN Brno 1;  Interní hematologická a onkologická klinika LF MU a FN Brno 2;  Katedra laboratorních metod, LF MU, Brno 3
Published in: Transfuze Hematol. dnes,30, 2024, No. Ahead of Print, p. 1-10.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2024prolekare.cz16

Overview

 Introduction: Optimal substitutional treatment includes measuring FVIII activity (FVIII:C) using the one-stage clotting assay (OSA) or chromogenic substrate assay (CSA). However, with the advent of FVIII concentrates with an extended half-life, discrepancies between methods have increased due to modifications of the FVIII molecule. Aim: Evaluation of OSA and CSA discrepancy in patients treated with extended half-life FVIII concentrates. Method: FVIII:C measurement by OSA with reagents Cephascreen® (Diagnostica Stago) and Pathromtin® SL (Siemens Healthineers) and by CSA BIOPHENTM FVIII:C (Hyphen BioMed) in patients treated with efmoroctocog alfa, rurioctocog alfa pegol, turoctocog alfa pegol and damoctocog alfa pegol. Results: The results of both methods correlated well for efmoroctocog alfa, the differences being up to 21%. The results of rurioctocog alfa pegol in the range of 15–200% were slightly lower using OSA with both reagents, on average by 11% and 18%, while the results up to 10% were higher using OSA with an average difference of 54% for Cephascreen® and up to 75% for Pathromtin® SL. The results of turoctocog alfa pegol were lower using OSA in the range of 15–200%, on average by 36% and 25%. The samples with FVIII:C above 10% of damoctocog alfa pegol were slightly higher using OSA (Cephascreen® by 18%), but samples up to 10% were significantly higher, with Cephascreen® on average by 91% and by 100% with Pathromtin® SL. Conclusions: OSA Cephascreen® or Pathromtin® SL and CSA Hyphen correlate excellently in the case of efmoroctocog alfa. Of the other concentrates, the results correlate excellently in the case of rurioctocog alfa pegol (only Cephascreen®) and damoctocog alfa pegol, and only for FVIII:C > 10%.

Keywords:

haemophilia A – FVIII activity – EHL concentrates

Sources
    1. Young GA, Perry DJ; for The International Prophylaxis Study Group (IPSG). Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice. J Thromb Haemost. 2019;17:567–573.
    2. Marlar RA, Strandberg K, Shima M, Adcock DA. Clinical utility and impact of the use of the chromogenic vs one‐stage factor activity assays in haemophilia A and B. Eur J Haematol. 2020;104:3–14. 
    3. Pruthi RK. Laboratory monitoring of new hemostatic agents for hemophilia. Semin Hematol. 2016;53:28–34.
    4. Smejkal P, Blatný J, Hajšmanová Z, et al. Konsenzuální doporučení Českého národního hemofilického programu (ČNHP) pro diagnostiku a léčbu pacientů s hemofilií, vydání 3., rok 2021. Transfuze Hematol Dnes. 2021;27(1):73–90.
    5. Gray E, Kitchen S, Bowyer A, et al. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2020;26:6–16.
    6. Jeanpierre E, Pouplard C, Lasne D, et al. Factor VIII and IX assays for post‐infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT). Eur J Haematol. 2020;105:103–115.
    7. Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia: Impact of factor and non‐factor replacement therapy on coagulation assays. J Thromb Haemost. 2020;18:1242–1255.
    8. Augustsson C, Norström E, Andersson NG, Zetterberg E, Astermark J, Strandberg K. Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre– and postinfusion samples. Res Pract Thromb Haemost. 2020;4:1114–1120.
    9. Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practise: guidance from UKHCDO. Haemophilia. 2016;22:487–498.
    10. Hubbard AR, Dodt J, Lee T, et al. Recommendations onthe potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost. 2013;11:988–989.
    11. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14:248–261.
    12. Škorňová I, Slavík L, et al. Faktory vnitřní koagulační cesty (FVIII, FIX, FXI a FXII). In: Hemostáza: laboratorní metody, jejich využití a interpretace ve vybraných klinických situacích. 2. vyd. Olomouc, Univerzita Palackého v Olomouci, 2021; 66-73.
  2. Srivasta A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. https:/ / onlinelibrary. wiley.com/ doi/ 10.1111/ hae.14046, přístup 25.10.2023.
  3. Bowyer AE, Duncan EM, Antovic JP. Role of chromogenic assays in haemophilia A and B diagnosis. Haemophilia. 2018;24:578–583.
  4. Souhrn údajů o přípravku Elocta®. https:// www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_ cs.pdf, přístup 3.11.2023
  5. Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9:295–308.
  6. Souhrn údajů o přípravku Adynovi®. https://www.ema.europa.eu/en/documents/product-information/ adynovi-epar-product-information_cs.pdf, přístup 3.11.2023
  7. Turecek PL, Romender-Finger S, Apostol C, et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C aktivity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 2016;22:957–965.
  8. Souhrn údajů o přípravku Esperoct®. https://www.ema.europa.eu/en/documents/product--information/esperoct-epar-product-information_cs.pdf, přístup 3.11.2023
  9. Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8‐GP; ESPEROCT®) assay performance: Implications for postadministration monitoring. Haemophilia. 2020;26:156–163.
  10. Church N, Leong L, Katterle Y, et al. Factor VIII activity of BAY 94‐9027 is accurately measured with most commonly used assays: Results from an international laboratory study. Haemophilia. 2018;24:823–832.
  11. Souhrn údajů o přípravku Jivi®. https://www. ema.europa.eu/ en/ documents/product-information/ jivi-epar-product-information_cs.pdf, přístup 3.11.2023
  12. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155–163.
  13. Lowe A, Jennings I, Kitchen S. One stage and chromogenic FVIII assay results at trough levels: a UK national external quality assessment scheme for blood coagulation (UK NEQAS BC) exercise. Haemophilia. 2020; 26:27.
  14. Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII aktivity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clottting and chromogenic assay kits: a two-centre study. Haemophilia. 2017;23:458–465.
  15. Pickering W, Hansen M, Kjalke M, Ezban M. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8‐GP. J Thromb Haemost. 2016;14:1579–1587.
  16. Van den Bossche D, Peerlinck K, Jacquemin M. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hem. 2018;40(Suppl. 1):21–29.
  17. Cinotti S, Paladino E, Morfini M. Accuracy of FVIII:C assay by one-stage method can be improved using hemophilic plasma as diluent. J Thromb Haemost. 2006;4:828–833.

  18. PODÍL AUTORŮ NA PŘÍPRAVĚ RUKOPISU

    MP – laboratorní diagnostika, napsání rukopisu

    SP, RG – léčba pacientů, revize rukopisu

    CHD, ZJ – laboratorní diagnostika, revize rukopisu

    ZJ – laboratorní diagnostika, revize rukopisu

    PM, BA – revize rukopisu

    ČESTNÉ PROHLÁŠENÍ

    Autoři práce prohlašují, že v souvislosti s tématem, vznikem a publikací tohoto článku nejsou ve střetu zájmů a vznik ani publikace článku nebyly podpořeny žádnou farmaceutickou firmou.

    PODĚKOVÁNÍ

    Podpořeno MZ ČR-RVO (FNBr, 65269705) a grantem MUNI/A/1558/2023.

    Do redakce doručeno dne: 31. 1. 2024.
    Přijato po recenzi dne: 8. 7. 2024.

    Mgr. Marie Prudková
    Oddělení klinické hematologie FN Brno
    Jihlavská 340/20 625 00 Brno
    e-mail:     prudkova.marie@fnbrno.cz

Labels
Haematology Internal medicine Clinical oncology
Primary mediastinal large B-cell lymphoma
Article was published in

Transfusion and Haematology Today

Issue Ahead of Print
2024 Issue Ahead of Print
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#